A carregar...
Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
BACKGROUND: We describe the clinical benefit of immune checkpoint inhibitors using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and ASCO VF. METHODS: We identify all approved indications of immune checkpoint inhibitors based on RCTs between January 1, 201...
Na minha lista:
| Publicado no: | BMC Cancer |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7457752/ https://ncbi.nlm.nih.gov/pubmed/32867707 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07313-2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|